On October 25, 2023 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, reported that an abstract about SBP-101 and CPP1X (also known as DFMO or Eflornithine) research in multiple myeloma (cell lines), has been accepted for an online publication on the American Society of Hematology (ASH) (Free ASH Whitepaper) meeting site in the November supplemental issue of the journal Blood (Press release, Panbela Therapeutics, OCT 25, 2023, https://panbela.com/press-release/acceptance-of-polyamine-inhibitor-car-t-combination-abstract-for-online-publication/?utm_source=rss&utm_medium=rss&utm_campaign=acceptance-of-polyamine-inhibitor-car-t-combination-abstract-for-online-publication [SID1234636330]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The work reflects the company’s on-going collaboration with researchers from The University of Texas MD Anderson Cancer Center and will become part of the permanent ASH (Free ASH Whitepaper) and Blood abstracts archive.
• Additional meeting information can be found on the ASH (Free ASH Whitepaper) website: View Source
• The abstract will also be available on the company’s website at View Source once the information has been released by ASH (Free ASH Whitepaper).